Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7739878 | 1.00 | DUT (0.41) | DUT | |
| SCHEMBL2828996 | 1.00 | DUT (0.41) | DUT | |
| SCHEMBL30378662 | 0.88 | DUT (0.36) | DUT | |
| SCHEMBL57968 | 0.86 | DUT (0.34) | DUT | |
| SCHEMBL925192 | 0.84 | DUT (0.37) | DUT | |
| SCHEMBL11580466 | 0.81 | DUT (0.42) | DUT | |
| SCHEMBL29284186 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL30612911 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL26510570 | 0.80 | DUT (0.41) | DUT | |
| SCHEMBL20088142 | 0.80 | DUT (0.41) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025129135-A2 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025076044-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119143737-A | Tetrahydrofuran carboxamide sodium channel regulator and application thereof in medicine | 嘉兴安帝康生物科技有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2021119503-A1 | CONTROLLED-DELIVERY CROMAKALIM PRODRUGS | QLARIS BIO, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| US-6596885-B2 | As antiestrogenic and anti-proliferative agent | AVENTIS PHARMA S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20020072624-A1 | New 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions | ROUSSEL UCLAF | 2002-06-13 | — | — | US | disclosed |
| US-6281204-B1 | ANTIESTROGENS | Roussel, Hoechst Marion (FR) | 2001-08-28 | — | — | US | disclosed |
| US-5750553-A | ANTIANDROGENIC AGENTS | ROUSSEL UCLAF (FR) | 1998-05-12 | — | — | US | disclosed |
| EP-0738263-A1 | NOVEL OPTIONALLY SUBSTITUTED PHENYLIMIDAZOLIDINES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018794-A1 | NOVEL OPTIONALLY SUBSTITUTED PHENYLIMIDAZOLIDINES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | KRAS, HRAS, NRAS | DUT 3908/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DUT 4056/4885 |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | KRAS, HRAS, NRAS | DUT 3931/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DUT 4056/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DUT 4056/4885 |
| US-20020072624-A1 | New 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions | HSD17B11, NR5A1, CYP19A1 | DUT 423/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DUT 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.